Api Business News Today

Biocon API business: Biocon has refuted claims of considering the sale of its generic active pharmaceutical ingredient (API) business, valued at $1.5 billion, to alleviate its debt burden. A company spokesperson clarified they were not assessing divestment options or seeking advice from bankers, countering an ET report based on insights from familiar sources.

Kotak Strategic Situations Fund (KSSF) plans to invest around ₹1,600 crore in the active pharmaceutical ingredients (API) business acquired by Nimmagadda Prasad. The fund will support the acquisition through a $200 million funding, provided through a mix of structured debt and equity. Deutsche Bank and DBS have also reportedly financed the acquisition.

Nimmagadda Prasad, the founder of Matrix Laboratories, has bought back the active pharmaceutical ingredients (API) business he sold to Mylan NV (now Viatris) in 2006. The acquisition was made through IQuest Enterprises, owned by Prasad. Viatris will retain some selective R&D capabilities in API while divesting its womens healthcare business to Insud Pharma.

Suspicious, let us know. when i was arrested in 2020, my first reaction was oh my god, the pi business is in peril. something will happen to another pi. we cannot let that happen. so, my wife was the one who was contacting numerous pi associations across the country and letting them know about these fox hunt operations. why is my wife calling numerous pis and letting them know? that should have been the job of the fbi. >> and, you spent so many years as a private investigators. one of the questi...

The company had explored a stake sale in its active pharmaceutical ingredient (API) business in 2019 but then opted for a listing in 2021 after spinning off the entity as Glenmark Life Sciences